A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system.

Amantadine has been proved to be beneficial in Parkinson's disease. Although it is still uncertain which neurochemical events are modified at therapeutic doses, an increase in dopaminergic tone secondary to NMDA receptor blockade and a direct inhibition of the glutamatergic overactivity have been suggested to be involved in its clinical effects. The aim of this study was to evaluate the effects of amantadine on the dopaminergic system by measuring the in vivo binding of [11-C]raclopride to D2 dopamine receptors in the basal ganglia of 6 patients with idiopathic Parkinson's disease. Each patient underwent a PET study, before and after 14 days of treatment with amantadine (200 mg/day). Repeated treatment with therapeutic doses of amantadine induced a moderate increase in the in vivo binding of [11C]raclopride in the putamen of PD patients. This observation indicates that in PD patients, 200 mg/day amantadine does not produce an increase in extracellular levels of dopamine sufficiently to inhibit raclopride binding or that, if present, is it masked by a concurrent increase in receptor availability, as recently reported in rat striatum.
AuthorsM A Volonté, R M Moresco, C Gobbo, C Messa, A Carpinelli, G Rizzo, G Comi, F Fazio
JournalNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (Neurol Sci) Vol. 22 Issue 1 Pg. 107-8 (Feb 2001) ISSN: 1590-1874 [Print] Italy
PMID11487182 (Publication Type: Journal Article)
Chemical References
  • Carbon Radioisotopes
  • Dopamine Agents
  • Dopamine Antagonists
  • Receptors, Dopamine D2
  • Raclopride
  • Levodopa
  • Amantadine
  • Dopamine
  • Aged
  • Amantadine (metabolism, therapeutic use)
  • Binding, Competitive (drug effects, physiology)
  • Carbon Radioisotopes (metabolism)
  • Dopamine (metabolism)
  • Dopamine Agents (metabolism, therapeutic use)
  • Dopamine Antagonists (metabolism)
  • Drug Interactions (physiology)
  • Female
  • Humans
  • Levodopa (metabolism, therapeutic use)
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy, radionuclide imaging)
  • Presynaptic Terminals (drug effects, metabolism)
  • Putamen (drug effects, radionuclide imaging)
  • Raclopride (metabolism)
  • Radioligand Assay
  • Receptors, Dopamine D2 (drug effects, metabolism)
  • Tomography, Emission-Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: